Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,859 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tumor burden with AFP improves survival prediction for TACE-treated patients with HCC: An international observational study☆.
Xia D, Bai W, Wang Q, Chung JW, Adhoute X, Kloeckner R, Zhang H, Zeng Y, Sripongpun P, Nie C, Kim SU, Huang M, Hu W, Ding X, Yin G, Li H, Zhao H, Bronowicki JP, Li J, Li J, Zhu X, Wu J, Zhang C, Gong W, Li Z, Lin Z, Xu T, Yin T, Anty R, Song J, Shi H, Shao G, Ren W, Zhang Y, Yang S, Zheng Y, Xu J, Wang W, Zhu X, Fu Y, Liu C, Kaewdech A, Ding R, Zheng J, Liu S, Yu H, Zheng L, You N, Fan W, Zhang S, Feng L, Wang G, Zhang P, Li X, Chen J, Zhang F, Shao W, Zhou W, Zeng H, Cao G, Huang W, Jiang W, Zhang W, Li L, Feng A, Wang E, Wang Z, Han D, Lv Y, Sun J, Ren B, Xia L, Li X, Yuan J, Wang Z, Luo B, Li K, Guo W, Yin Z, Zhao Y, Xia J, Fan D, Wu K, Bettinger D, Vogel A, Han G; China HCC-TACE study group. Xia D, et al. Among authors: yin z, yin t, yin g. JHEP Rep. 2024 Sep 12;7(1):101216. doi: 10.1016/j.jhepr.2024.101216. eCollection 2025 Jan. JHEP Rep. 2024. PMID: 39758510 Free PMC article.
Phase 2 study of serplulimab with the bevacizumab biosimilar HLX04 in the first-line treatment of advanced hepatocellular carcinoma.
Ren Z, Shao G, Shen J, Zhang L, Zhu X, Fang W, Sun G, Bai Y, Wu J, Liu L, Yuan Y, Zhang J, Li Z, Zhang L, Yin T, Wu J, Hou X, Yu H, Li J, Wang Q, Zhu J, Fan J; Serplulimab-HCC Investigators. Ren Z, et al. Among authors: yin t. Cancer Immunol Immunother. 2025 Jan 3;74(2):69. doi: 10.1007/s00262-024-03917-w. Cancer Immunol Immunother. 2025. PMID: 39751879 Free PMC article. Clinical Trial.
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, Yopp AC, Zhou J, Wang L, Wen X, Heo J, Tak WY, Nakamura S, Numata K, Uguen T, Hsiehchen D, Cha E, Hack SP, Lian Q, Ma N, Spahn JH, Wang Y, Wu C, Chow PKH; IMbrave050 investigators. Qin S, et al. Lancet. 2023 Nov 18;402(10415):1835-1847. doi: 10.1016/S0140-6736(23)01796-8. Epub 2023 Oct 20. Lancet. 2023. PMID: 37871608 Clinical Trial.
2,859 results